Physician profile
Michael Gindi
NPI 1225667769
$1,480.42
in general payments reported to CMS, 2019-2025
9 companies · $586 in 2025
The $586 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $399 · 2023: $64.53 · 2024: $431 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $491.15 | 2023-2025 | Fasenra, Airsupra |
| Abiomed | $234.18 | 2024-2025 | |
| Novo Nordisk INC | $224.05 | 2022 | |
| Janssen Scientific Affairs, LLC | $125.16 | 2024 | Stelara |
| Verona Pharma, INC. | $102.66 | 2025 | Ohtuvayre |
| Esperion Therapeutics, INC. | $94.80 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.22 | 2022 | |
| Boston Scientific Corporation | $65.31 | 2024 | Compliance Endokit, Resolution 360 Clip |
| Inspire Medical Systems, INC. | $62.89 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gindi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.